[go: up one dir, main page]

AR007101A1 - Derivados de acido 4-arilbutirico sustituido como inhibidores de la metaloproteasa de matriz - Google Patents

Derivados de acido 4-arilbutirico sustituido como inhibidores de la metaloproteasa de matriz

Info

Publication number
AR007101A1
AR007101A1 ARP970101981A ARP970101981A AR007101A1 AR 007101 A1 AR007101 A1 AR 007101A1 AR P970101981 A ARP970101981 A AR P970101981A AR P970101981 A ARP970101981 A AR P970101981A AR 007101 A1 AR007101 A1 AR 007101A1
Authority
AR
Argentina
Prior art keywords
phenyl
alkyl
benzyl
pharmaceutically acceptable
formula
Prior art date
Application number
ARP970101981A
Other languages
English (en)
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of AR007101A1 publication Critical patent/AR007101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/04—1,2,3-Triazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos inhibidores de la metaloproteasa de matriz, composiciones farmacéuticas que los contienen y un proceso para usar los mismos a fin detratar una diversidad de trastornos fisiológicos. Los compuestos de la presente invención tienen lafórmula generalizada (I) donde R1 representa alquilo C6-C12alcoxi C5C12, alquiltio C5-C12 un polieter de la fórmula R2O(C2H4O)a donde a es 1 o 2 y R2 es alquilo C1-C5 fenilo o bencilo y alquinilo sustituido de lafórmula R3(CH2)b-C=C- en la cual el bes 1-10 y R3 es H- HO- o R4O- donde R2 es alquilo C1-C3 fenilo o bencilo. Las porciones alquilo, fenilo y bencilo de R1pueden contener por lo menos un sustituyente farmacéuticamente aceptable. El subíndice n es 2-4 R5 es fenilo, imidoilo de 4-12á tomos de carbono (3H)-benzo-1,2,3-triazin-4-on-3-ilo: N sacarinilo; (2H)-ftalazin-1-on-2-ilo: 2- benzoxazolin-2-on-3-ilo 5,5-dimetiloxazolidin-2 4-dion-3-ilo y tiazolidin-2,4-dion-3-ilo, las porciones fenilo y benzo de R5 puedencontener p or lo menos un sustituyente farmacéuticamente aceptable. También están incluidas las salesfarmacéuticamente aceptables de estos materiales.
ARP970101981A 1996-05-15 1997-05-12 Derivados de acido 4-arilbutirico sustituido como inhibidores de la metaloproteasa de matriz AR007101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64768296A 1996-05-15 1996-05-15

Publications (1)

Publication Number Publication Date
AR007101A1 true AR007101A1 (es) 1999-10-13

Family

ID=24597888

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101981A AR007101A1 (es) 1996-05-15 1997-05-12 Derivados de acido 4-arilbutirico sustituido como inhibidores de la metaloproteasa de matriz

Country Status (21)

Country Link
EP (1) EP0923529B1 (es)
JP (1) JP3354941B2 (es)
CN (1) CN1225620A (es)
AR (1) AR007101A1 (es)
AT (1) ATE205822T1 (es)
AU (1) AU727468B2 (es)
BR (1) BR9709075A (es)
CA (1) CA2253795C (es)
CO (1) CO5011113A1 (es)
DE (1) DE69706874T2 (es)
ES (1) ES2160955T3 (es)
HR (1) HRP970247B1 (es)
ID (1) ID17326A (es)
MY (1) MY116903A (es)
PA (1) PA8429501A1 (es)
SV (1) SV1997000033A (es)
TN (1) TNSN97086A1 (es)
TW (1) TW442468B (es)
WO (1) WO1997043237A1 (es)
YU (1) YU18897A (es)
ZA (1) ZA974033B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970245B1 (en) 1996-05-15 2002-06-30 Bayer Ag Biaryl acetilenes as matrix metalloprotease inhibitors
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
FR2832925B1 (fr) * 2001-12-03 2006-07-14 Lipha Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation
JP2012087113A (ja) * 2010-09-22 2012-05-10 Daicel Corp フェニル酢酸化合物
JP2017509665A (ja) * 2014-04-03 2017-04-06 バイエル ファーマ アクチエンゲゼルシャフト 気道疾患治療のための２，５−ジ置換されたシクロペンタンカルボン酸類
WO2015150364A1 (de) * 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Substituierte benzotriazinonbutansäuren und ihre verwendung
US20170022171A1 (en) 2014-04-03 2017-01-26 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentanecarboxylic acids and their use
US20170119776A1 (en) 2014-04-03 2017-05-04 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
WO2015189117A1 (de) * 2014-06-12 2015-12-17 Bayer Pharma Aktiengesellschaft Heterobicyclisch substituierte 4-oxobutansäure-derivate und ihre verwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE650081A (es) * 1963-07-03
FR2378741A1 (fr) * 1977-02-01 1978-08-25 Fabre Sa Pierre Acides garyl goxo isovaleriques doues de proprietes antiphlogistiques et antalgiques
ATE214368T1 (de) 1995-12-22 2002-03-15 Warner Lambert Co Aromatische keto-säure und ihre derivate als inhibitoren der matrix metalloproteinase
CO5011071A1 (es) 1996-05-15 2001-02-28 Bayer Corp Inhibicion de las metaloproteinasas de matriz por acidos 2-(w/aroilalquil)-4-biaril-4-oxobutiricos y composiciones farmaceuticas que los contienen

Also Published As

Publication number Publication date
CN1225620A (zh) 1999-08-11
AU2938997A (en) 1997-12-05
HRP970247A2 (en) 1998-04-30
ATE205822T1 (de) 2001-10-15
DE69706874D1 (en) 2001-10-25
AU727468B2 (en) 2000-12-14
EP0923529A1 (en) 1999-06-23
TW442468B (en) 2001-06-23
YU18897A (en) 1999-11-22
WO1997043237A1 (en) 1997-11-20
MY116903A (en) 2004-04-30
ID17326A (id) 1997-12-18
JP3354941B2 (ja) 2002-12-09
EP0923529B1 (en) 2001-09-19
ZA974033B (en) 1998-02-19
PA8429501A1 (es) 2000-05-24
JPH11510518A (ja) 1999-09-14
DE69706874T2 (de) 2002-03-28
CO5011113A1 (es) 2001-02-28
SV1997000033A (es) 1999-01-14
ES2160955T3 (es) 2001-11-16
HRP970247B1 (en) 2002-02-28
CA2253795C (en) 2002-10-15
TNSN97086A1 (fr) 2005-03-15
BR9709075A (pt) 1999-08-03
CA2253795A1 (en) 1997-11-20

Similar Documents

Publication Publication Date Title
NO960393L (no) Heterosykliske fenylforbindelser som COX-2-inhibitorer
CO5700824A2 (es) Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
AR017844A1 (es) Derivados de benzamidina, procedimiento para prepararlos, empleo de los mismos para preparar un medicamento, composicion farmaceutica que los contiene yprocedimiento para obtenerla
DK1052254T3 (da) Nitrogen-holdig heterocykliske derivater og medicin deraf
NO20024217L (no) 1,5-benzotiazepiner og deres anvendelse som hypolidmidler
HRP20031098B1 (en) Beta-amino tetrahydroimidazo (1,2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
PT83310B (pt) Processo para a preparacao de derivados de indol heterociclicamente substituiods, de produtos intermediarios para a sua preparacao e de composicoes farmaceuticas que os contem
AR023659A1 (es) Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR041184A1 (es) Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
AR022019A1 (es) Un compuesto de imidazol y las composiciones farmaceuticas que lo contienen
EA200000614A1 (ru) 2,3-замещенные соединения индола в качестве ингибиторов сох-2
EA200400223A1 (ru) Новые производные 2h-пиридазин-3-она, фармацевтические композиции, содержащие эти производные, и способ получения активного ингредиента
AR007101A1 (es) Derivados de acido 4-arilbutirico sustituido como inhibidores de la metaloproteasa de matriz
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
PE20040698A1 (es) Derivados de isoindolina
AR056762A1 (es) (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
UY26564A1 (es) Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos
EA200600570A1 (ru) Замещенные 2-карбониламино-6-пиперидинаминопиридины и замещенные 1-карбониламино-3-пиперидинаминобензолы как агонисты 5-ht
AR035765A1 (es) Composiciones fungicidas de n-2-piridinilmetilbenzamida y del propil ester de acido (3-(dimetilamino)-propil) carbamico; procedimientos curativos o preventivos contra hongos fitopatogenos de cultivos, utilizando dichas composiciones y productos de aplicacion combinada, simultanea, separada o secuenc
DK0514942T3 (da) Hidtil ukendte benzopyranderivater og fremgangsmåder til fremstilling deraf

Legal Events

Date Code Title Description
FB Suspension of granting procedure